Global Medical Affairs Team and Asset Leader
BioNTech
Summary
As the Global Medical Affairs Team and Asset Leader, you will take the helm of a Medical Affairs Team (MAT), crafting and driving the medical strategy for a defined brand, indication, or asset scope. Your leadership will integrate cross-functional expertise across Development, Global Product Strategy, Publications, Scientific Communications, Evidence Generation, HEOR, Pricing and Reimbursement, and regional/local medical teams to deliver a unified medical vision. This role is pivotal in shaping BioNTech’s success by translating scientific innovation into impactful strategies that address high medical needs.
Job description
About the Role
As the Global Medical Affairs Team and Asset Leader, you will take the helm of a Medical Affairs Team (MAT), crafting and driving the medical strategy for a defined brand, indication, or asset scope. Your leadership will integrate cross-functional expertise across Development, Global Product Strategy, Publications, Scientific Communications, Evidence Generation, HEOR, Pricing and Reimbursement, and regional/local medical teams to deliver a unified medical vision. This role is pivotal in shaping BioNTech’s success by translating scientific innovation into impactful strategies that address high medical needs.
You will thrive in a collaborative environment where your strategic thinking and oncology expertise will influence global medical direction. At BioNTech, we empower you to lead with purpose while fostering an inclusive workplace that values diversity and innovation.
Your Contribution
- Lead a Medical Affairs Team (MAT) and define the overarching medical strategy for one brand/indication or equivalent asset scope
- Develop and maintain a coherent medical plan encompassing evidence generation, scientific communications, publications, HEOR, field medical needs, and external engagement priorities
- Act as the formal cross-functional integrator for decision-making across Development, GPS, Publications, Scientific Communications, HEOR, Pricing and Reimbursement
- Translate scientific data into actionable strategies and differentiated medical positioning
- Provide senior-level input into launch preparations, lifecycle planning, and governance discussions
- Incorporate country and regional perspectives into global strategies where relevant
- Mentor junior Medical Directors and contribute to capability-building within Medical Affairs
- Serve as the escalation point for complex asset-level trade-offs and prioritization decisions
A Good Match
- MD required with demonstrated oncology expertise for Senior/Executive levels; relevant oncology experience for Associate level
- Extensive experience in senior oncology Medical Affairs or Clinical Development roles within pharma or biotech industries
- Proven track record of leading major initiatives in matrixed organizations with cross-functional teams
- Strong external scientific credibility coupled with excellent stakeholder management skills
- Strategic thinker with deep oncology knowledge who excels in navigating complexity
- Exceptional communication skills with demonstrated ability to align diverse stakeholders
Requirements
- MD required with demonstrated oncology expertise for Senior/Executive levels; relevant oncology experience for Associate level
- Extensive experience in senior oncology Medical Affairs or Clinical Development roles within pharma or biotech industries
- Proven track record of leading major initiatives in matrixed organizations with cross-functional teams
- Strong external scientific credibility coupled with excellent stakeholder management skills
- Strategic thinker with deep oncology knowledge who excels in navigating complexity
- Exceptional communication skills with demonstrated ability to align diverse stakeholders
Benefits
- Health Insurance
- Annual Bonus
- Equity
Company overview
BioNTech SE is a pioneering German multinational biotechnology company headquartered in Mainz, Germany, that specializes in developing innovative immunotherapies and vaccines for cancer and infectious diseases. Founded in 2008 by scientists Uğur Şahin, Özlem Türeci, and Christoph Huber, the company gained global recognition for co-developing the first approved mRNA-based COVID-19 vaccine with Pfizer. BioNTech's core expertise lies in mRNA technology, which it has been researching for over 15 years, with applications spanning individualized cancer medicine, infectious disease prevention, and novel therapeutic approaches. The company operates a diversified portfolio including mRNA cancer immunotherapies, next-generation immunomodulators, targeted therapies, and antibody-drug conjugates. With approximately 6,800 employees across more than 20 global sites, BioNTech maintains a strong focus on oncology, advancing multiple late-stage clinical programs while expanding its infectious disease pipeline to address conditions like malaria, tuberculosis, and mpox. The company's strategic acquisitions, including InstaDeep for AI capabilities and CureVac for mRNA expertise, further strengthen its position as a leader in next-generation biopharmaceutical innovation.